Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2022 | Biomarkers to help predict response to CDK4/6 inhibitors

Seth Wander • 7 Dec 2022
SABCS 2022
Breast Cancer

Seth Wander, MD, PhD, Massachusetts General Hospital, Boston, MA, discusses the development of new biomarkers that can help predict which patients are most likely to benefit from CDK4/6 inhibitors. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Seth Wander

0:50
Investigating mechanisms of resistance to CDK4/6 inhibitors
Seth Wander • 7 Dec 2022
2:07
TAKTIC: ipatasertib, endocrine therapy and CDK4/6i for patients with HR+/HER2- mBC
Seth Wander • 7 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals